A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
for Advanced Breast Cancer
15 locations incl. Hot Springs
Sponsor: TerSera Therapeutics LLC
Sex: Female·Age: 18 - 55
Code: NCT07310420·Phase 1·Recruiting·Listed Dec 2025